Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes
Status:
Completed
Trial end date:
2017-08-31
Target enrollment:
Participant gender:
Summary
An increased risk of incident diabetes with statin therapy have been reported in several
studies. However, it is not recommended to limit the use of statin for this reason since the
absolute risk increase was small, and the cardiovascular event rate reduction with statins
overweighed the risk of new diabetes (Scatter N et al. Lancet, 2010). Moreover, each statin
may have different effect on the development of incident diabetes. In the West of Scotland
Coronary Prevention Study, pravastatin therapy reduced the hazard of becoming diabetic by
30%. Also, with pravastatin use, an increase in adiponectin level, which is related to the
improvement in insulin sensitivity, has been reported. In this clinical trial, the
investigators are aiming to evaluate the effect of pravastatin on insulin resistance, insulin
secretion, glycemic control, and adiponectin level in participants with prediabetes or early
diabetes by assigning them in a 24 weeks of pravastatin therapy group or in a placebo group.